Experience of treating patients with mixed hypertriglyceridemia in a lipid center (clinical case)

Lipid metabolism disorders remain a significant medical and social problem associated with mortality, disability, morbidity and pathologies of the circulatory system. According to international and Russian epidemiological studies, hypertriglyceridemia is a common risk factor for coronary heart disease. Isolated use of non-pharmacological therapy and statin monotherapy is not effective enough, and therefore it is necessary to propagate the experience of combined treatment, supported by modern recommendations. This work shows the possibilities of effective use of combined therapy of lipid metabolism disorders (statin, ezetimibe, alirocumab, fenofibrate) in patients with mixed hypertriglyceridemia.